Key questions employers should ask their PBM about GLP-1s As oral GLP-1s join formularies, employers should be discussing these key questions with their PBM, looking beyond coverage decisions to what will truly drive outcomes: Patient selection: How do you identify clinically appropriate candidates, not just anyone requesting treatment
If it persists, a psyllium-based supplement may be worth discussing with your provider
During your initial week, Dr
We are located at 150 Overlook Ave, Hackensack, NJ 07601
The TRIUMPH-1 trial for Retatrutide showed a 28.3% average weight reduction, while Tirzepatide's SURMOUNT-1 trial showed a 20.9% reduction
Accordingly, the observed association should be interpreted in the context of a small absolute increase in risk, particularly when weighted against the established metabolic and cardiovascular benefits of GLP-1RA therapy